

Piero G Sismondi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3595349/piero-g-sismondi-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80
papers

3,571
citations

33
h-index

59
g-index

82
ext. papers

3,818
ext. citations

4.9
avg, IF

4.2
L-index

#	Paper	IF	Citations
80	Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5138-47	2.2	375
79	Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. <i>Lancet Oncology</i> , 2009 , 10, 135-46	21.7	236
78	Menopause after breast cancer: a survey on breast cancer survivors. <i>Maturitas</i> , 2003 , 45, 29-38	5	213
77	Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. <i>Breast Cancer Research and Treatment</i> , 2004 , 83, 67-76	4.4	207
76	Overexpression of the Met/HGF receptor in ovarian cancer. <i>International Journal of Cancer</i> , 1994 , 58, 658-62	7.5	197
75	Overexpression of the RON gene in human breast carcinoma. <i>Oncogene</i> , 1998 , 16, 2927-33	9.2	172
74	FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. <i>Genes Chromosomes and Cancer</i> , 1993 , 7, 219-26	5	144
73	Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. <i>Cancer</i> , 1995 , 75, 1327-38	6.4	109
72	Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. <i>Gynecological Endocrinology</i> , 2010 , 26, 404-12	2.4	97
71	Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. <i>PLoS ONE</i> , 2008 , 3, e2238	3.7	89
70	Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. <i>Breast Cancer Research and Treatment</i> , 1996 , 40, 171-8	4.4	84
69	A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. <i>Journal of Molecular Endocrinology</i> , 2004 , 32, 719-75	4.5	74
68	c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. <i>International Journal of Cancer</i> , 1991 , 47, 833-8	7.5	73
67	Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1891-900	1.1	72
66	Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. <i>Clinical Chemistry</i> , 2002 , 48, 1241-1250	5.5	72
65	Vaginal oestrogen therapy after breast cancer: is it safe?. <i>European Journal of Cancer</i> , 2005 , 41, 2673-81	7.5	70
64	Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. <i>International Journal of Cancer</i> , 2008 , 123, 1327-38	7.5	68

63	AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. <i>FASEB Journal</i> , 2008 , 22, 2702-14	0.9	63
62	Comparison of two models for the prediction of nonsentinel node metastases in breast cancer. <i>American Journal of Surgery</i> , 2007 , 193, 686-92	2.7	61
61	Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. <i>Gynecological Endocrinology</i> , 2013 , 29, 263-7	2.4	60
60	New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. <i>Maturitas</i> , 2005 , 52, 1-10	5	56
59	Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. <i>Endocrine-Related Cancer</i> , 2007 , 14, 549-67	5.7	55
58	Role of transvaginal sonography in the detection of endometriomata. <i>Journal of Clinical Ultrasound</i> , 1995 , 23, 163-7	1	49
57	Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. <i>European Journal of Cancer</i> , 2012 , 48, 2311-8	7.5	47
56	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. <i>European Radiology</i> , 2007 , 17, 1490-7	8	45
55	Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5547-51	2.2	43
54	The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 78, 149-58	4.4	41
53	Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. <i>Journal of Cellular Physiology</i> , 2004 , 200, 440-50	7	39
52	Axillary reverse mapping in breast cancer: can we spare what we find?. <i>Annals of Surgical Oncology</i> , 2008 , 15, 390-1; author reply 392-3	3.1	37
51	Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2006 , 98, 1163-84	4.7	37
50	Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. <i>Gynecological Endocrinology</i> , 2005 , 20, 343-60	2.4	36
49	Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial. <i>Maturitas</i> , 2011 , 70, 365-72	5	35
48	Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. <i>European Radiology</i> , 2005 , 15, 1224-33	8	33
47	The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999 , 54, 101-7	4.4	31
46	Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. <i>Maturitas</i> , 1994 , 19, 25-31	5	31

45	Hormone replacement therapy in cancer survivors. <i>Maturitas</i> , 2004 , 48, 333-46	5	27
44	Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. <i>Breast Cancer Research</i> , 2012 , 14, R13	8.3	25
43	Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. <i>Cancer</i> , 2007 , 109, 1060-7	6.4	25
42	Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. <i>Breast Journal</i> , 2007 , 13, 490-5	1.2	25
41	Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. <i>Gynecological Endocrinology</i> , 2010 , 26, 568-77	2.4	24
40	Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'Suntranslated region. <i>Biochemical Journal</i> , 2004 , 377, 429-38	3.8	24
39	Aromatase inhibitors for breast cancer: different structures, same effects?. <i>Endocrine-Related Cancer</i> , 2008 , 15, 27-36	5.7	22
38	Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. <i>Gynecological Endocrinology</i> , 2009 , 25, 807-15	2.4	21
37	Antihormones in prevention and treatment of breast cancer. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1089, 143-58	6.5	21
36	Laparoscopic treatment of endometrial cancer: feasibility and results. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006 , 124, 232-6	2.4	17
35	Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. <i>Journal of Pathology</i> , 2013 , 229, 390-9	9.4	16
34	Results of treatment of uterine cervix cancer by radiotherapy. <i>Radiotherapy and Oncology</i> , 1988 , 13, 257-65	5.5	15
33	Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. <i>Oncology</i> , 2010 , 78, 274-81	3.6	12
32	Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes. <i>Maturitas</i> , 2007 , 57, 50-5	5	12
31	Personal use of hormone therapy by postmenopausal women doctors and male doctorsSwives in Italy after the publication of WHI trial. <i>Maturitas</i> , 2006 , 54, 181-92	5	12
30	Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens. <i>Maturitas</i> , 2003 , 45, 283-91	5	11
29	Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. <i>International Journal of Cancer</i> , 1998 , 79, 147-52	7.5	10
28	Hormonal replacement therapy after gynaecological cancer. <i>Gynakologisch-geburtshilfliche Rundschau</i> , 2006 , 46, 191-6		10

27	Personal use of HRT by postmenopausal women doctors and doctorsSwives in the north of Italy. <i>Gynecological Endocrinology</i> , 2004 , 18, 165-74	2.4	10
26	Chemoprevention or mastectomy for women at high risk of developing breast cancer. <i>Maturitas</i> , 2015 , 82, 271-3	5	7
25	AP-2alpha regulates migration of GN-11 neurons via a specific genetic programme involving the Axl receptor tyrosine kinase. <i>BMC Biology</i> , 2009 , 7, 25	7.3	7
24	Insulin-like growth factor-I and risk of breast cancer. <i>Lancet, The</i> , 1998 , 352, 488-9	4.0	7
23	Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 883-4; author reply 884-5	9.7	7
22	Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2004 , 95, 323-9	4.9	6
21	Transient ventricular hypocinesia after in utero anthracyclines exposure: a case-report and review of the literature. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012 , 25, 189-92	2	5
20	Safe management of cesarean section in a patient of Eisenmenger syndrome. <i>Annals of Cardiac Anaesthesia</i> , 2012 , 15, 296-8	1.3	5
19	HRT, breast and endometrial cancers: strategies and intervention options. <i>Maturitas</i> , 1999 , 32, 131-9	5	5
18	Pathological classification of ductal carcinoma in situ of the breast correlates with surgical treatment and may be predicted by mammography. <i>Breast</i> , 2007 , 16, 495-502	3.6	4
17	Semi-open direct trocar insertion method for induction of pneumoperitoneum at laparoscopy. <i>Gynaecological Endoscopy</i> , 2002 , 11, 197-200		4
16	HRT and gynaecologic cancer after WHI: old stuff or new doubts?. <i>Maturitas</i> , 2004 , 48, 13-8	5	4
15	Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?. <i>Clinical Breast Cancer</i> , 2021 , 21, e53-e62	3	4
14	Association between ovarian endometriosis and malignancy in the peri-menopausal period: report of two cases and review of the literature. <i>Gynecological Surgery</i> , 2010 , 7, 13-17	1.7	2
13	Laparoscopic dissection of the ureter for radical laparoscopic hysterectomy. <i>Gynecological Surgery</i> , 2005 , 2, 179-182	1.7	2
12	Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial. <i>Oncology</i> , 2001 , 60, 221-7	3.6	2
11	Prognostic value of estrogen receptors determined by radiochemical vs. histochemical methods in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1985 , 6, 67-73	4.4	2
10	Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients. <i>Breast Cancer</i> , 2021 , 28, 1131-1140	3.4	2

9	Laparoscopic bipolar coagulation of hypogastric artery in postpartum haemorrhage: a case report. <i>Case Reports in Obstetrics and Gynecology</i> , 2011 , 2011, 250325	0.8	1
8	Patients with breast cancer are unlikely to benefit from prophylactic irradiation of the contralateral breast. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1014-5; author reply 1015-6	2.2	1
7	Hormone-replacement therapy and lobular cancers: new deals and old myths. <i>Expert Review of Endocrinology and Metabolism</i> , 2008 , 3, 287-290	4.1	1
6	Progesterone receptor and human epidermal growth factor receptor 2 status: an independent influence on the efficacy of endocrine therapy in breast cancer?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1481-2; author reply 1482	2.2	1
5	Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. <i>Cancer</i> , 2002 , 94, 579-80; author reply 581-3	6.4	1
4	Term breech trial. <i>Lancet, The</i> , 2001 , 357, 226-7; author reply 227-8	4.0	1
3	Treatment of Menopausal Symptoms in Breast Cancer Survivors. <i>ISGE Series</i> , 2018 , 223-232	0.2	
2	The Academic Division of Breast and Gynaecological Oncology of the Institute for Cancer Research and Treatment (IRCC) of Candiolo, Turin, Italy. <i>Breast Care</i> , 2008 , 3, 287-288	2.4	
1	Risk-Reducing Surgery and Treatment of Menopausal Symptoms in BRCA Mutation Carriers (and Other Risk Women). <i>ISGE Series</i> , 2018 , 205-213	0.2	